Imsidolimab

DB16658InvestigationalProtein Based Therapies

Imsidolimab is under investigation in clinical trial NCT03633396 (A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis).

Mechanism: Pharmacologically active on Interleukin-1 receptor-like 2
Curator reviewed
Code names: ANB-019

Resolves to

Compound

UNIIKX89J0DFZ8CAS2102543-86-0

Targets

Q9HB29IL1RL2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Imsidolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account